Lecanemab Clears Amyloid via Microglia and Fc Receptors
A 2026 Nature Neuroscience study found that lecanemab cleared amyloid in a humanized-microglia Alzheimer’s disease model only when microglia and the antibody’s intact Fc fragment were both present: X-34 plaque area differed across IgG1, lecanemab, and Fc-silenced LALA-PG groups (P = 0.0003), 82E1 plaque area differed across groups (P < 0.0001), and microglia-deficient mice showed …